PPL Electric Utilities has disclosed a data breach. It's tied to the 2023 breach involving MOVEit, a type of file transfer software. Hackers were able to steal files from companies and agencies around ...
Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...
(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (NUVL) (Nasdaq: ...
This package provides a network bridge which enables the exchange of messages between ROS 1 and ROS 2. To use ros1_bridge, you must use a system where both ROS 1 and ROS 2 are installable and ...
On July 31, 2025, the District of Massachusetts issued two rulings largely denying motions to dismiss filed by software developer Progress Software Corporation (“Progress”) and certain direct users or ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Ritwik is a passionate gamer who has a soft spot for JRPGs. He's been writing about all things gaming for six years and counting. No matter how great a title's gameplay may be, there's always the ...
Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer. At the 2025 IASLC World ...
An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, ...
Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results